The Systemic Immune Network in Recent Onset Type 1 Diabetes: Central Role of Interleukin-1 Receptor Antagonist (DIATOR Trial)

• Hubert Kolb ,

  * E-mail: hubert.kolb@uni-duesseldorf.de

  Affiliation West-German Centre of Diabetes and Health, Verbund Katholischer Kliniken Düsseldorf, Düsseldorf, Germany

  ⨯
• Kathrin Lückemeyer,

  Affiliation Profil Institute for Metabolic Research, Neuss, Germany

  ⨯
• Tim Heise,

  Affiliation Profil Institute for Metabolic Research, Neuss, Germany

  ⨯
• Christian Herder,

  Affiliation Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany

  ⨯
• Nanette C. Schloot,

  Current address: Lilly Deutschland GmbH, Bad Homburg, Germany

  Affiliation Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany

  ⨯
• Wolfgang Koenig,

  Affiliation Department of Internal Medicine II - Cardiology, University of Ulm Medical Center, Ulm, Germany

  ⨯
• Lutz Heinemann,

  Affiliation Profil Institute for Metabolic Research, Neuss, Germany

  ⨯
• Stephan Martin,

  Affiliation West-German Centre of Diabetes and Health, Verbund Katholischer Kliniken Düsseldorf, Düsseldorf, Germany

  ⨯
• on behalf of the DIATOR Study Group

  ¶Membership of the DIATOR Study Group Consortium is provided in the Acknowledgments.

  ⨯